Literature DB >> 16011104

[The dynamic effect of yiqi qingwen jiedu heji on the protein expressions of cytokine IFN-gamma, TNF-alpha, IL-10 and IL-6 in the lungs of mice infected by IV FM1].

Cheng-xiang Wang1, Gui-xin Gao, Shou-chao Wei, Hong-ri Xu.   

Abstract

OBJECTIVE: To find the function and functioning mechanism of Yiqi Qingwen Jiedu Heji in resisting influenza immune damage by studying its effect on the expressions of cytokine.
METHOD: Taking IV FM1 infected mice as its model and doing ELISA (double antibody sandwichenzyme linked immunosorbent assay), we dynamically observed the change of cytokine TNF-alpha, IL-6, IFN-gamma and IL-10 after giving Yiqi Qingwen Jiedu Heji treatment. RESULT AND
CONCLUSION: After the mice are infected by influenza virus, their protein expressions of the model group are higher than those of the control group, of which TNF-alpha, IL-6, IFN-gamma reach the peak in three days. The three expressions of Yiqi Qingwen Jiedu Heji treated group are decreased and the decrease becomes remarkable on the third day, compared with those of the model group. However, the expression of IL-10 of the treated group is remarkably increased. It indicates that Yiqi Qingwen Jiedu Heji can resist the expressions of TNF-alpha, IL-6 and IFN-gamma pro-inflammatory cytokine,increase the expression of IL-10, and thus, alleviate inflammatory injury. So the clinical application of such medicine can shorten the course of disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16011104

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  2 in total

1.  Inhibitory effects and related molecular mechanisms of total flavonoids in Mosla chinensis Maxim against H1N1 influenza virus.

Authors:  Xiao-Xia Zhang; Qiao-Feng Wu; Yun-Liang Yan; Feng-Ling Zhang
Journal:  Inflamm Res       Date:  2017-11-24       Impact factor: 4.575

2.  Using Complementary and Alternative Medicines to Target the Host Response during Severe Influenza.

Authors:  Lisa M Alleva; Charles Cai; Ian A Clark
Journal:  Evid Based Complement Alternat Med       Date:  2009-09-24       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.